![Michael Altman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Altman
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2026
Profil
Michael R.
Altman is the founder of ARYA Sciences Acquisition Corp., founded in 2018, where the title held was Chief Financial Officer & Director from 2018 to 2020.
Mr. Altman is the founder of ARYA Sciences Acquisition Corp.
II, founded in 2020, with the title Chief Financial Officer & Director in 2020.
Mr. Altman is the founder of ARYA Sciences Acquisition Corp.
III, founded in 2020, holding the title Chief Financial Officer & Director from 2020 to 2021.
Mr. Altman is the founder of ARYA Sciences Acquisition Corp.
IV, founded in 2020, with the title Chief Financial Officer & Director from 2021 to 2024.
Mr. Altman is the founder of ARYA Sciences Acquisition Corp.
V, founded in 2021, holding the title Chief Financial Officer & Director from 2021 to 2023.
Mr. Altman is the founder of Perceptive Capital Solutions Corp., founded in 2024, holding the titles Director & Chief Business Officer starting in 2024.
Current jobs include Director at Vitruvias Therapeutics, Inc. since 2017; Director at Vensun Pharmaceuticals, Inc. since 2016; Director at Covid Apollo Project LLC; Head of Strategy at Perceptive Advisors LLC starting in 2025; and Head of Strategy at Perceptive Advisors (Private Equity) since 2007.
Former jobs include Independent Director at Nautilus Biotechnology, Inc. from 2021 to 2025; Independent Director at Lyra Therapeutics, Inc. from 2018 to 2024; Healthcare Analyst at First New York Securities LLC in 2007; and Vice President at Mako Merger Sub, Inc. Education includes an undergraduate degree from the University of Vermont, conferred in 2004.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.06.2025 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Michael Altman
| Unternehmen | Position | Beginn |
|---|---|---|
Perceptive Advisors LLC
 Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. | Analyst-Festverzinsliche Wertpapiere | 01.10.2007 |
Vitruvias Therapeutics, Inc.
 Vitruvias Therapeutics, Inc. Medical/Nursing ServicesHealth Services Researches and develops generic drugs | Direktor/Vorstandsmitglied | - |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors invests in both public and private middle market companies located across the globe. The firm focuses across a broad range of sectors and industries. It participates in seed, early, later stage and growth transactions in the form of equity and debt with an investment size of USD 10 – 300 million. The firm acts as lead investor and takes a seat on a board of directors. | Corporate Officer/Principal | - |
Vensun Pharmaceuticals, Inc.
 Vensun Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Direktor/Vorstandsmitglied | 01.11.2016 |
Covid Apollo Project LLC
 Covid Apollo Project LLC Financial ConglomeratesFinance Operates investment company that funding is based on Covid-19 testing and finding solution | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Michael Altman
| Unternehmen | Position | Ende |
|---|---|---|
| NAUTILUS BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 20.06.2025 |
| LYRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 12.12.2024 |
| ARYA SCIE | Gründer | 01.08.2024 |
| ARYA SCIENCES ACQUISITION CORP V | Gründer | 01.07.2023 |
| ░░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░░ ░ | ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Michael Altman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
65
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Perceptive Advisors LLC
Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. | Finance |
Vensun Pharmaceuticals, Inc.
Vensun Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Vitruvias Therapeutics, Inc.
Vitruvias Therapeutics, Inc. Medical/Nursing ServicesHealth Services Researches and develops generic drugs | Health Services |
First New York Securities LLC
 First New York Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
University of Vermont
 University of Vermont Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lyra Therapeutics, Inc.
 Lyra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage therapeutics company which develops and commercializes novel integrated drugs for treatment of patients with ear, nose and throat and ENT diseases | Health Technology |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors invests in both public and private middle market companies located across the globe. The firm focuses across a broad range of sectors and industries. It participates in seed, early, later stage and growth transactions in the form of equity and debt with an investment size of USD 10 – 300 million. The firm acts as lead investor and takes a seat on a board of directors. | Finance |
ARYA Sciences Acquisition Corp.
 ARYA Sciences Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
ARYA Sciences Acquisition Corp. II
 ARYA Sciences Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
ARYA Sciences Acquisition Corp. III
 ARYA Sciences Acquisition Corp. III Financial ConglomeratesFinance Operates as a blank check company | Finance |
ARYA Sciences Acquisition Corp. IV
 ARYA Sciences Acquisition Corp. IV Financial ConglomeratesFinance Operates as a blank check company | Finance |
Covid Apollo Project LLC
Covid Apollo Project LLC Financial ConglomeratesFinance Operates investment company that funding is based on Covid-19 testing and finding solution | Finance |
Nautilus Biotechnology, Inc.
 Nautilus Biotechnology, Inc. BiotechnologyHealth Technology Develops proteomics platform for analyzing and quantifying the human proteome | Health Technology |
Mako Merger Sub, Inc. | |
ARYA Sciences Acquisition Corp. V
 ARYA Sciences Acquisition Corp. V Financial ConglomeratesFinance Operates as a blank check company | Finance |
